IV drip therapy works from the inside out, so the changes are gradual rather than instant
NICE guidance recommends reviewing GLP-1 therapy at 6 months, continuing only if HbA1c has reduced by at least 11 mmol/mol and weight has decreased by at least 3% of initial body weight for diabetes treatment

References: Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus Ian J Neeland, Darren K McGuire, Robert Chilton, Susanne Crowe, Sren S Lund, Hans J Woerle, Uli C Broedl, Odd Erik Johansen, 2016 (sagepub.com) SGLT2 Inhibitors and the Mechanisms Involved in Weight Loss | Current Pharmacology Reports (springer.com) Empagliflozin for the treatment of type 2 diabetes: Expert Opinion on Pharmacotherapy: Vol 15, No 16 (tandfonline.com) label (fda.gov) Semaglutide as a promising antiobesity drug Christou 2019 Obesity Reviews Wiley Online Library Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis PubMed (nih.gov) Post by: Dr.Marcella Jiovanni Health and Beauty Expert Marcella Jiovanni actively promotes the importance of maintaining healthy skin, she envisions the future of dermatology as moving away from pure medical, pharmacological dermatology and flowing more toward a holistic approach to wellness and skincare.

We believe essential healthcare should be affordable for everyone, which is why weve spent two decades bridging the gap between rising domestic costs and the medications you need to stay healthy
Receptor activity: With less interference, IGF-1 DES binds more efficiently to IGF-1 receptors on muscle and connective tissue cells